|
gptkbp:instanceOf
|
gptkb:drug
protease inhibitor
|
|
gptkbp:administeredBy
|
subcutaneous injection
intravenous injection
|
|
gptkbp:approvalYear
|
2003
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XX32
|
|
gptkbp:brand
|
gptkb:Velcade
|
|
gptkbp:CASNumber
|
179324-69-7
|
|
gptkbp:category
|
antineoplastic agent
orphan drug
boronic acid derivative
|
|
gptkbp:chemicalFormula
|
C19H25BN4O4
|
|
gptkbp:contraindication
|
pregnancy
hypersensitivity to boron
|
|
gptkbp:cost
|
high
|
|
gptkbp:developedBy
|
gptkb:Millennium_Pharmaceuticals
|
|
gptkbp:discoveredBy
|
gptkb:Julian_Adams
|
|
gptkbp:discoveredIn
|
1995
|
|
gptkbp:eliminationHalfLife
|
40 hours
|
|
gptkbp:firstBook
|
yes
|
|
gptkbp:genericAvailable
|
yes
|
|
gptkbp:hasBoxedWarning
|
risk of peripheral neuropathy
risk of thrombocytopenia
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bortezomib
|
|
gptkbp:interactsWith
|
CYP3A4 inhibitors
CYP3A4 inducers
green tea extract
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits 26S proteasome
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
384.24 g/mol
|
|
gptkbp:origin
|
synthetic
|
|
gptkbp:patentExpired
|
2017 (US)
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
83%
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
peripheral neuropathy
thrombocytopenia
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:synonym
|
gptkb:PS-341
LDP-341
|
|
gptkbp:UNII
|
QPL8W5568D
|
|
gptkbp:usedFor
|
gptkb:mantle_cell_lymphoma
multiple myeloma
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Mantle_Cell_Lymphoma
|
|
gptkbp:bfsLayer
|
7
|